Oscar Health (NYSE:OSCR) Issues Quarterly Earnings Results

Oscar Health (NYSE:OSCR) announced its quarterly earnings results on Thursday. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.70, FiscalAI reports. The company had revenue of $4.88 billion for the quarter, compared to the consensus estimate of $4.73 billion. Oscar Health had a return on equity of 44.96% and a net margin of 3.60%.The firm’s revenue for the quarter was up 70.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.89) EPS.

Here are the key takeaways from Oscar Health’s conference call:

• Strong profitability and raised outlook: Oscar reported $1.1 billion in first-half earnings from operations and $1 billion in net income. Management raised full-year earnings-from-operations guidance by $250 million to $500 million–$700 million while maintaining its revenue outlook.
• Membership and operating metrics improved materially: Effectuated membership increased 46% year over year to 2.96 million, revenue rose 70% to $4.9 billion, and second-quarter MLR improved nearly 12 points to 79.2%. The SG&A ratio fell 450 basis points to a record-low 14.2%.
• Favorable medical trends provide potential upside: Inpatient, professional, and pharmacy utilization were favorable, while outpatient utilization was elevated but stable. Early 2026 morbidity data was better than pricing assumptions, although Oscar has not fully reflected that potential benefit in its guidance.
• Technology and AI are driving efficiency: Oscar said its AI-enabled claims, pharmacy, care-navigation, and member-support tools are reducing costs and improving productivity. The company expects its pharmacy analytics and related initiatives to generate tens of millions of dollars in annual savings and sees additional SG&A leverage ahead.
• Enrollment churn is expected to increase in the second half: CMS eligibility and program-integrity reviews are expected to produce disenrollments that were delayed from the second quarter, with churn potentially approaching twice the previously expected 1%–2% monthly rate. Management said the financial impact is included in guidance and primarily reflects timing rather than a fundamental change in retention.

Oscar Health Price Performance

Shares of Oscar Health stock traded up $1.39 during trading hours on Friday, reaching $27.93. The stock had a trading volume of 10,468,402 shares, compared to its average volume of 4,846,594. The stock’s 50 day moving average is $28.93 and its 200 day moving average is $20.37. The firm has a market capitalization of $8.42 billion, a PE ratio of 19.95, a PEG ratio of 1.35 and a beta of 2.36. Oscar Health has a twelve month low of $10.69 and a twelve month high of $33.10. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26.

More Oscar Health News

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Substantial earnings and revenue beat: Oscar reported quarterly EPS of $1.10, versus the $0.40–$0.43 analyst consensus, compared with a $0.89 loss in the year-ago quarter. Revenue rose 70.4% to $4.88 billion, exceeding estimates of approximately $4.73 billion. Oscar Health Inc. Q2 Earnings Beat Estimates
• Positive Sentiment: Profitability improved sharply: The insurer generated approximately $361 million of second-quarter profit and more than $1 billion in net income during the first half, helped by membership growth and easing medical costs. Oscar Health Reports Another Big Profit
• Positive Sentiment: Full-year outlook was raised: Oscar increased its 2026 revenue forecast to $18.7 billion–$19.0 billion, above the roughly $18.6 billion consensus estimate, and indicated $500 million–$700 million in earnings from operations with an 81.5%–82.5% medical-loss-ratio target. Oscar Health Signals 2026 Earnings Outlook
• Neutral Sentiment: The results reinforce Oscar’s improving profit-turnaround story, with technology and operational execution remaining important to managing a changing customer base. Oscar Health 2026 Profit Turnaround
• Negative Sentiment: Churn outlook pressured the shares: Management’s forecast for elevated member churn raised concerns about retention, future enrollment growth and whether the unusually strong earnings can be sustained. That concern reportedly outweighed the quarterly beat and guidance increase. Oscar Health Falls as Churn Forecast Overshadows Q2 Beat

Analyst Ratings Changes

OSCR has been the topic of a number of recent research reports. Piper Sandler restated an “overweight” rating and issued a $36.00 target price on shares of Oscar Health in a research note on Tuesday, July 28th. Robert W. Baird set a $27.00 price target on Oscar Health in a research report on Friday. Wells Fargo & Company set a $20.00 price target on Oscar Health and gave the company an “equal weight” rating in a report on Thursday, June 4th. Zacks Research upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Finally, Jefferies Financial Group upgraded Oscar Health from an “underperform” rating to a “hold” rating and upped their price objective for the stock from $10.00 to $16.00 in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $24.00.

Insider Activity

In related news, Director Mario Schlosser sold 147,500 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $29.38, for a total value of $4,333,550.00. Following the completion of the transaction, the director owned 1,360,866 shares of the company’s stock, valued at approximately $39,982,243.08. This represents a 9.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Mark T. Bertolini sold 624,244 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $28.48, for a total value of $17,778,469.12. Following the transaction, the chief executive officer owned 7,751,570 shares in the company, valued at $220,764,713.60. This represents a 7.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 3,662,466 shares of company stock worth $105,145,815. 22.64% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Strs Ohio purchased a new position in shares of Oscar Health during the 1st quarter valued at approximately $30,000. Jones Financial Companies Lllp increased its holdings in Oscar Health by 7,473.3% in the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock worth $30,000 after acquiring an additional 2,242 shares in the last quarter. Quarry LP increased its holdings in Oscar Health by 439.8% in the 3rd quarter. Quarry LP now owns 1,803 shares of the company’s stock worth $34,000 after acquiring an additional 1,469 shares in the last quarter. Binnacle Investments Inc acquired a new position in Oscar Health during the second quarter worth $75,000. Finally, National Bank of Canada FI acquired a new position in Oscar Health during the third quarter worth $81,000. 75.70% of the stock is owned by institutional investors and hedge funds.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.